Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 790 | 121 | 646 |
| Samples | 385 | 75 | 299 |
| Peptides | 307 | 47 | 255 |
Function
ORC1 · Origin recognition complex subunit 1
The origin recognition complex (ORC) is a highly conserved six subunits protein complex essential for the initiation of the DNA replication in eukaryotic cells. Studies in yeast demonstrated that ORC binds specifically to origins of replication and serves as a platform for the assembly of additional initiation factors such as Cdc6 and Mcm proteins. The protein encoded by this gene is the largest subunit of the ORC complex. While other ORC subunits are stable throughout the cell cycle, the levels of this protein vary during the cell cycle, which has been shown to be controlled by ubiquitin-mediated proteolysis after initiation of DNA replication. This protein is found to be selectively phosphorylated during mitosis. It is also reported to interact with MYST histone acetyltransferase 2 (MyST2/HBO1), a protein involved in control of transcription silencing. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2010].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 307 amino-acid changes on canonical ENST00000371568 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ORC1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ORC1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 5/54 9% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 17/612 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Gastric Carcinoma | 3/74 4% | 28/1809 2% |
| Melanoma | 2/210 1% | 32/1899 2% |
| Colorectal Carcinoma | 13/143 9% | 39/3239 1% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 14/1390 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Bladder Carcinoma | 2/58 3% | 9/956 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 9/810 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 17/1592 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Neuroendocrine Tumour | 4/154 3% | 3/577 1% |
| Hepatocellular Carcinoma | 2/46 4% | 19/2210 1% |
| Burkitts Lymphoma | 1/32 3% | 1/196 1% |
| Other Solid Cancers | 0/94 0% | 14/1515 1% |
| Ovarian Carcinoma | 3/109 3% | 6/998 1% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 17/2550 1% |
| Breast Carcinoma | 4/144 3% | 20/3264 1% |
| Esophageal Carcinoma | 0/23 0% | 5/769 1% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Sarcomas | 1/69 1% | 3/699 0% |
| Head and Neck Carcinoma | 0/85 0% | 8/1574 1% |
| Meningioma | 0/3 0% | 1/252 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Pancreatic Carcinoma | 2/89 2% | 4/1611 0% |
Mutation Distribution
Where ORC1 is mutated · all tissues, split by cell line vs tissue
How many mutations in ORC1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 790 mutations in ORC1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|